Reduced volume SIB-IMRT/IGRT to head and neck cancer in elderly and frail patients: outcome and toxicity

被引:13
|
作者
Straube, Christoph [1 ]
Pigorsch, Steffi U. [1 ]
Scherb, Hagen [2 ]
Wilkens, Jan J. [1 ]
Bier, Henning [4 ]
Combs, Stephanie E. [1 ,3 ]
机构
[1] TUM, Dept Radiat Oncol, Klinikum Rechts Isar, Ismaninger Str 22, D-81675 Munich, Germany
[2] Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Inst Computat Biol, Helmholtz Zentrum Munchen, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany
[3] Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Inst Innovat Radiotherapy IRT, Helmholtz Zentrum Munchen, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany
[4] TUM, Dept Otorhinolaryngol Head & Neck Surg, Ismaninger Str 22, D-81675 Munich, Germany
关键词
SQUAMOUS-CELL CARCINOMA; PHASE-III TRIAL; PALLIATIVE RADIOTHERAPY; INCURABLE HEAD; COMORBIDITY; IMPACT; GY;
D O I
10.1186/s13014-016-0711-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Especially elderly and frail patients have a limited ability to compensate for side effects of a radical treatment of head and neck malignancies. Limiting the target volume to the macroscopic disease, without prophylactic nodal irradiation, might present a feasible approach for these patients. The present work therefore aims evaluating an IMRT/IGRT-SIB concept for safety and efficacy. Methods: The study retrospectively enrolled 27 patients with head and neck cancers treated between 01/2012 and 05/2015. We evaluated patient files for clinical status, concomitant diseases, treatment side, and treatment volumes as well as for side effects and tumor responses. To describe efficacy and risk factors for worse outcome and higher grade toxicities, we performed cox regression analysis as well as Kaplan-Meier survival time analysis. Results: Median survival was 181 days, 75 % patients showed an early local response at six weeks of follow up. Most patients developed mild to moderate acute toxicities, only one patient with grade IV mucositis was seen. The grade of toxicities was correlated to the size of the PTV. Concomitant diseases, metastatic disease, and G3 Grading were indicators for worse prognosis. Conclusion: The IMRT/IGRT SIB concept is a safe and feasible radiotherapy concept for patients not able or not willing to undergo radical treatment.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Reduced volume SIB-IMRT/IGRT to head and neck cancer in elderly and frail patients: outcome and toxicity
    Christoph Straube
    Steffi U. Pigorsch
    Hagen Scherb
    Jan J. Wilkens
    Henning Bier
    Stephanie E. Combs
    [J]. Radiation Oncology, 11
  • [2] SIB-IMRT with adaptive replanning for head and neck cancer
    Lee, J.
    Yang, D.
    Kim, C.
    Yoon, W.
    Park, Y.
    Lee, N.
    Woo, J.
    Cho, J.
    Kim, J.
    Kang, E.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2014, 111 : S35 - S36
  • [3] Long term outcome and late toxicity of SIB-IMRT in definitive management of head and neck cancers in patients not suitable for chemo-Radiotherapy
    Singh, Narayan Pratap
    Khurana, Rohini
    Sapru, Shantanu
    Rastogi, Madhup
    Gandhi, Ajeet Kumar
    Rath, Satyajeet
    Hadi, Rahat
    Mishra, Surendra Prasad
    Srivastava, Anoop Kumar
    Bharti, Avinav
    Sahni, Kamal
    Ali, Mohammad
    Tiwari, Ramakant
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2022, 18 (06) : 1461 - 1468
  • [4] Monte Carlo-based dosimetry of head-and-neck patients treated with SIB-IMRT
    Sakthi, N
    Keall, P
    Mihaylov, I
    Wu, QW
    Wu, Y
    Williamson, JF
    Schmidt-Ullrich, R
    Siebers, JV
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (03): : 968 - 977
  • [5] EVALUATION OF TOXICITY AND EFFECTIVENESS OF SIB-IMRT RADIOTHERAPY GIVEN CONCOMITANTLY WITH CISPLATIN FOR LOCALLY ADVANCED SQUAMOUS CELL HEAD AND NECK CANCER.
    Kiprian, D.
    Kawecki, A.
    Jarzabski, A.
    Pawlowska-Sendulka, B.
    Michalski, W.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2011, 98 : S28 - S29
  • [6] Accelerated hypofractionation with SIB-IMRT in Anal Cancer : assessment of efficacy and toxicity
    Lucidi, S.
    Bertini, N.
    Loi, M.
    Bonomo, P.
    Francolini, G.
    Greto, D.
    Simontacchi, G.
    Galardi, A.
    Marrazzo, L.
    Allegra, A.
    Guerrieri, B.
    Scoccimarro, E.
    Mariotti, M.
    Carnevale, M. G.
    Stocchi, G.
    Ciccone, L. P.
    Peruzzi, A.
    Lorenzetti, V.
    Talamonti, C.
    Pallotta, S.
    Mangoni, M.
    Livi, L.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2022, 170 : S1118 - S1120
  • [7] Modulated Radiation Dose Fractionations of Combined SIB-IMRT and Monoclonal Antibody Treatment in Head and Neck Cancer
    Pedicini, P.
    Mazziotta, M.
    Castaldo, G.
    Barbieri, V.
    Sanpaolo, P.
    Aieta, M.
    Fusco, V.
    [J]. ONCOLOGY, 2009, 77 : 154 - 155
  • [8] Preliminary results of SIB-IMRT in head and neck cancers: Report from a regional cancer center in northern India
    Chakraborty, Santam
    Ghoshal, Sushmita
    Patil, Vijay M.
    Oinam, Arun S.
    Sharma, Suresh C.
    [J]. JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2009, 5 (03) : 165 - 172
  • [9] THE EVALUATION OF THE EARLY RESULTS AND TOXICITY OF SIB-IMRT RADIOTHERAPY GIVEN CONCOMITANTLY WITH CISPLATIN FOR LOCALLY ADVANCED SQUAMOUS CELL HEAD AND NECK CANCER (SCHNC)
    Kiprian, D.
    Jarzabski, A.
    Pawlowska-Sendulka, B.
    Kawecki, A.
    Laskus, Z.
    Michalski, W.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2010, 96 : S331 - S331
  • [10] Safety and feasibilty of SIB-IMRT in combination with chemotherapy and/or targeting agents in patients with locoregionally advanced head and neck cancer in the definitive or postoperative setting
    Khalil, Ahmad D.
    Mose, S.
    Stromberger, C.
    Wust, P.
    Budach, V
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2016, 192 : 93 - 93